Agree johnrusso,
We can all sympathize with those who invested their hard earned in PBT today, but imo the outcome for PBT investors also emphasizes how much OBJ remains undervalued today. Without knowing the results of multiple human clinical trials undertaken and fully funded by OBJ's multi-billion dollar partners we have already been made well aware by Jeff's recent AGM comments and the arrival of a global royalties expert that the primary outcome measures of ALL studies conducted with OBJ's technology platforms have been successful.
Ignoring the GlaxoSmithKline clinical trials and the increasing number of other Global Pharmaceutical giants being attracted to OBJ's disruptive technology platforms, while one could argue that the success of the P&G and Coty clinical studies are only relevant to a $250 billion dollar beauty market compared to the $950 billion pharmaceutical market, one could also argue that OBJ's Joint Development Partner is the world's largest marketing company and owner of the world's most valuable beauty brand.
As it's no longer a matter of if, but when, the market finally awakes, these facts will have to account for something towards the value of the company's securities.
On the topic of disruptive innovation in the pharmaceutical industry, consider for one moment the task of talking Eskimo's out of building Igloos with ice, because that's exactly what OBJ are doing... Talking Global Pharmaceutical companies out of pharmaceuticals.
2010 - Industry Expert to Head International PartneringOBJ Limited is pleased to announce the appointment of Dr. Kevin Hammond in a new executive role as OBJ’s International Partnering Manager. Dr Hammond has over 30 years experience with some of the world’s leading pharmaceutical, FMCG and cosmetic companies. His principal responsibilities have involved managing the partnering, licensing and new product innovations for companies such as Reckitt Benckiser, Unilever, PZ Cussons, CB Fleet (US) and GSK.
Dr Hammond commented that:“True innovation is becoming increasingly rare with regulatory barriers and increasing costs leading to more standardised products. OBJ’s
physical rather than chemical approach to product performance enhancement may change the balance in established product categories. Its application in the cosmetic, consumer and healthcare markets may offer similar opportunities to those in the pharmaceutical sector. I see my role with OBJ as an opportunity to be part of a highly committed team focused on delivering sustained growth.” -
Industry Expert to Head International Partnering
2012 Drug Delivery Partnerships Conference"John Baldoni, Ph.D., SVP platform technology and science R&D with GSK, discussed knowledge as becoming a commodity, and he predicts the next therapeutic game changer will come not from drugs, but electrons." -
Life Science Leader
2012 Drug Delivery Partnerships ConferenceIt's important to understand what we're doing today - it's not what we have been doing and secondly, the world is changing very dramatically, so if you look back and say how did we build a successful company in the past, the companies that we build going forward will be violently different... the question in the pharmaceutical industry is, can we adapt fast enough before we become extinct? -
G. Steven Burrill, CEO, Burrill & Company
2013 - Will Pharma Lead or Follow?There seems to be a bit of a disconnect between pharma and many of the innovations that are emerging. Perhaps it’s the very nature of these innovations that conflicts with the conservative pharmaceutical industry. Perhaps it’s still a period of ‘watchful waiting’. Or even, it could be yesterday’s brand managers, sales reps and administrators who, while caressing the piles of pills that define an industry, are just missing what many define as the next revolution since the personal computer.
Forbes - Will Pharma lead or follow
(20min delay)